No connection

Search Results

INM vs SPRC

INM
InMed Pharmaceuticals Inc.
BEARISH
Price
$0.72
Market Cap
$2.4M
Sector
Healthcare
AI Confidence
95%
SPRC
SciSparc Ltd.
BEARISH
Price
$4.42
Market Cap
$2.5M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
INM
--
SPRC
0.0
Forward P/E
INM
-0.11
SPRC
--
P/B Ratio
INM
0.21
SPRC
0.03
P/S Ratio
INM
0.53
SPRC
1.91
EV/EBITDA
INM
0.57
SPRC
--

Profitability

Gross Margin
INM
29.73%
SPRC
38.74%
Operating Margin
INM
-258.57%
SPRC
-569.52%
Profit Margin
INM
-170.07%
SPRC
0.0%
ROE
INM
-97.2%
SPRC
-1281.49%
ROA
INM
-49.77%
SPRC
--

Growth

Revenue Growth
INM
-26.2%
SPRC
--
Earnings Growth
INM
--
SPRC
--

Financial Health

Debt/Equity
INM
0.06
SPRC
--
Current Ratio
INM
5.94
SPRC
--
Quick Ratio
INM
4.85
SPRC
--

Dividends

Dividend Yield
INM
--
SPRC
--
Payout Ratio
INM
0.0%
SPRC
0.0%

AI Verdict

INM BEARISH

The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness across nearly all fundamental health dimensions. While the current ratio is high (5.94), this is offset by a catastrophic profit margin of -170.07% and declining year-over-year revenue growth of -26.20%. The stock is in a clear long-term death spiral, with a 5-year price change of -100% and a technical trend score of 0/100. Without a pivot to profitability or a significant capital infusion, the business model appears unsustainable.

Strengths
Very low Debt/Equity ratio (0.06) indicating minimal long-term debt burden
Strong short-term liquidity with a Current Ratio of 5.94
Positive Gross Margin (29.73%) suggesting the core product has some inherent value
Risks
Critical financial health as evidenced by a 1/9 Piotroski F-Score
Severe operational inefficiency with an Operating Margin of -258.57%
Negative revenue growth (-26.20% YoY) indicating shrinking market share or demand
SPRC BEARISH

SPRC exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a catastrophic ROE of -1281.49%. The company has experienced a massive valuation collapse, falling from a 52-week high of $94.50 to $4.42, representing a 91.7% decline over the last year. With an operating margin of -569.52% and a total lack of analyst coverage, the business model appears unsustainable. The recent 1-week price spike of 40.3% is likely a speculative 'dead cat bounce' rather than a fundamental recovery.

Strengths
Positive gross margin of 38.74%
Extremely low Price-to-Book ratio (0.03)
Recent short-term price volatility providing speculative entry points
Risks
Extreme bankruptcy risk indicated by negative ROE and weak F-Score
Severe operational inefficiency with -569.52% operating margin
Total collapse in long-term shareholder value (-100% 5Y change)

Compare Another Pair

INM vs SPRC: Head-to-Head Comparison

This page compares InMed Pharmaceuticals Inc. (INM) and SciSparc Ltd. (SPRC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile